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understanding of the relationship among 
UVR spectrum, skin area and exposure 
dose, skin color, tanning, photoprotec-
tion, and vitamin D outcome. Some of 
these issues in the context of risk/ben-
efit are currently being investigated in 
a multinational European Community–
funded project, “ICEPURE: The Impact of 
Climatic and Environmental Factors on 
Personal Ultraviolet Radiation Exposure 
and Human Health” (see http://www.
icepure.eu for details). Furthermore, we 
need a much better understanding of the 
relationship between the maintenance 
of vitamin D status by UVB versus diet/
supplementation and their interactions.
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Bogh MKB, Schmedes AV, Philipsen PA et al. 
(2010) Vitamin D production after UVB 
exposure depends on baseline vitamin D and 
were at the high end of suberythemal. 
This UVR protocol was equivalent to a 
vitamin D dose of 250 µg/day, which 
is 10,000 international units. A level of 
about ~100 nmol l-1 was reached at 3 
weeks, with about 70 nmol l-1 reached 
in 2 weeks. This daily supplement 
dose is 10 times higher than that rec-
ommended by the US Department of 
Health and Human Services and the US 
Department of Agriculture (Johnson and 
Kimlin, 2006).
Much of the advice pertaining to 
“safe sun” is based on the prevention of 
erythema because it is a readily accessi-
ble clinical readout, and sunburn is a risk 
factor for malignant melanoma in suscep-
tible skin types. It is possible to compare, 
in theory, the relative risks and benefits 
of solar exposure using action spectra 
(wavelength dependence) for erythema 
and the synthesis of pre–vitamin D (not 
25(OH)D) as biological weighting func-
tions with solar spectra with different 
UVB/UVA ratios. The amount of UVB 
increases with the height of the sun, 
which is dependent on latitude, sea-
son, and time of day. Such calculations 
indicate that the optimal benefit-to-risk 
ratio occurs when the sun is high in the 
sky (Sayre and Dowdy, 2007), which is 
when people are advised to avoid the 
sun (e.g., about noon). These calcula-
tions are based on action spectra, which 
are likely to have large margins of error, 
and it would be desirable to test these 
results under field or laboratory condi-
tions using 25(OH)D as the readout.
conclusions
The dermatology community is very 
mindful of the well-established detri-
mental effects of UVB. The commu-
nity is increasingly aware of the role of 
UVB in vitamin D synthesis but is still 
skeptical of many of the health benefits 
attributed to vitamin D. Researchers are 
justifiably concerned about the misuse 
of information for financial gain or the 
inadvertent promotion of sun-seeking/
tanning behavior. However, much work 
remains to be done in risk-versus-benefit 
assessment of UVR exposure, which 
will depend on a range of individual/
demographic/cultural/geographic factors 
and on the communication of research 
outcomes and advice to the public. 
There is a clear need for a much better 
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Cutaneous T-Cell Lymphoma:  
Two Faces of the same Coin
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Primary cutaneous anaplastic large-cell lymphoma (C-ALCL) and cutaneous 
peripheral T-cell lymphoma not otherwise specified (C-PTL-NOs) are cutaneous 
T-cell lymphomas with distinct clinical behaviors. Whereas C-ALCL has a favorable 
prognosis with frequent spontaneous disease regression, C-PTL-NOs runs a more 
aggressive course. The molecular pathogenesis of these cutaneous T-cell lymphoma 
types has not yet been studied in detail. In this issue, van Kester et al. report new 
imbalances that could contribute to our understanding of the differences between 
these two lymphoma types.
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Cutaneous T-cell lymphomas (CTCLs) 
are non-Hodgkin´s lymphomas char-
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term includes a growing variety of differ-
ent disorders, with specific clinical and 
histological features that require precise 
therapies. Cutaneous ana plastic large-
cell lymphoma (C-ALCL) and cutane-
ous peripheral T-cell lymphoma not 
otherwise specified (C-PTL-NOS) are 
distinct CTCLs with different progno-
ses. Whereas C-ALCL is characterized 
by strong and uniform CD30 expres-
sion with favorable prognosis (95% of 
patients have a 5-year survival), C-PTL-
NOS is an aggressive T-cell lymphoma 
with poor survival (16% of patients 
have a 5-year survival) (Willemze et 
al., 2005), and its diagnosis is based 
mainly on the lack of diagnostic mark-
ers that typify other CTCLs, including 
the absence of CD30 expression. The 
current clinicopathological classifica-
tion of these cutaneous lymphoprolif-
erative disorders, although improving 
continuously, remains insufficient and 
requires the incorporation of addi-
tional robust immunohistochemical or 
molecular markers. More importantly, 
targeted therapy necessitates a better 
understanding of the molecular patho-
genesis of CTCLs; treatment of C-PTL-
NOS with conventional chemotherapy 
is often disappointing because most 
patients die of their disease.
Information on chromosomal aber-
rations in CTCLs is remarkably scarce 
when compared with that on other 
neoplasms—in particular, the other 
lymphomas and leukemias. Most cyto-
genetic studies of primary CTCL have 
been based on the analysis of epider-
motropic lymphomas such as mycosis 
fungoides and its leukemic counter-
part, Sézary syndrome. Several factors 
contribute to this paucity of informa-
tion, including the phenotypic variety 
of the disease, difficulties in obtain-
ing substantial numbers of tumor cells 
from skin biopsies, and the absence 
or rarity of tumor cells in peripheral 
blood. In this issue, van Kester and 
colleagues (2010) report studies in 
which they took on the challenge 
of identifying genomic events that 
underlie the pathogenesis of C-ALCL 
and C-PTL-NOS. Using samples from 
CTCL patients, the authors have identi-
fied several novel alterations that dif-
ferentiate the molecular signature of 
C-ALCL from that of C-PTL-NOS.
trafficking of T cells to the skin (Homey 
et al., 2002). van Kester et al. describe 
the upregulation of CCR10, CCR7, 
CCR8, and CCR10 ligand–CCL27 in 
C-ALCL. Expression of these recep-
tors in peripheral T-cell lymphoma has 
been reported to be related to a favor-
able prognosis. The above findings 
indicate that the expression of chemot-
actic receptors could contribute to 
reduced tumor dissemination and con-
finement of the tumor to the skin.
nF-κB/cD30/traF1/IrF4,  
good friends in c-aLcL
Additionally, van Kester and colleagues 
(2010) confirm CD30 (TNFRSF8) as 
a highly expressed gene in C-ALCL, 
together with TRAF1 and IRF4. CD30 
activation causes upregulation of 
NF-κB, utilizing the tumor necrosis 
factor receptor–associated factors 
(TRAFs) as adaptor molecules (Duckett 
et al., 1997). Contrary to the earlier 
study reported by Assaf et al. (2007), 
TRAF1 was found by van Kester et al. 
to be upregulated in C-ALCL samples. 
Although little is known about the 
function of TRAF1, it is thought to 
be expressed primarily by activated 
lymphocytes, and it is involved in the 
intracellular signal transduction of 
tumor necrosis factor receptor fam-
ily members without death domains, 
such as CD30 (Figure 1a). In Hodgkin 
cells—another tumor characterized 
by the synchronous expression of 
CD30, TRAF1, and IRF4 with NF-κB 
activation—it has been demonstrated 
that CD30-induced alternative NF-κB 
activation is inhibited by the deple-
tion of TRAF1 expression (Guo et al., 
2009). This could constitute a scenar-
io comparable to that seen in C-ALCL. 
Similar to other CD30-positive lym-
phomas (Bonzheim et al., 2004), a 
defective TCR signaling pathway has 
been identified for C-ALCL. A dual 
role for the NF-κB pathway in tumor 
progression has also been suggested, 
oscillating between inhibition of 
tumor growth and tumor progression 
(Perkins, 2004). This is consistent with 
the observations reported in this issue 
by van Kester and colleagues and 
explains the occasional erratic clini-
cal course of C-ALCL (Willemze et 
al., 2005).
Using samples from 11 C-ALCL and 
10 C-PTL-NOS patients, van Kester 
et al. (2010) show that C-ALCL is char-
acterized by gains in chromosomes 7q, 
17, and 21 and losses in chromosomes 
3p, 6q, 8p, and 13q. In C-PTL-NOS, the 
authors demonstrate gains in chromo-
somes 1q, 6p, 7q, 8, 11q, 12, 14, 16q, 
17, and 19 and losses in chromosomes 
8p and 9p21. The numerous chromo-
somal alterations present in C-PTL-NOS 
could partly explain the aggressiveness 
of the disease. Despite the novelty and 
potential importance of these findings, 
further work is required to overcome 
some of limitations of this study, such 
as the relatively low number of patients 
and use of a noncommercial platform 
for array-based comparative genomic 
hybridization analysis, in addition to 
the as yet imprecise diagnostic criteria 
for C-PTL-NOS.
In contrast with C-PTL-NOS, CD30+ 
C-ALCL has an excellent prognosis. 
Based on gene expression data, van 
Kester et al. (2010) attribute the more 
favorable course of C-ALCL to the 
increased expression of skin-homing 
chemokine receptors. Chemokines can 
stimulate directional migration of near-
ly all classes of leukocytes. T cells from 
different functional subsets—T helper 
type 1 (Th1), Th2, Th17, regulatory T, 
naive, and memory—express a regu-
lated set of chemokine receptors that 
allow them to differentially respond 
to specific chemokines. Expression 
of multiple chemokines can attract a 
wide range of leukocytes, including 
the potential homing of T cells to the 
epidermis. Specifically, the chemokine 
receptors CCR4 and CCR10 have 
both been reported to participate in 
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Figure 1. Possible scenarios related to the molecular pathogenesis of cutaneous anaplastic large cell 
lymphoma (c-aLcL) and cutaneous peripheral t-cell lymphoma not otherwise specified (c-PtL-noS). (a) 
Role in skin homing for chemokine receptors (left) and the NF-κB pathway (right) in C-ALCL. Chemokine 
receptors have an important role in trafficking of malignant T cells in the skin. T cells migrate along a gradient 
of chemokines (e.g., CCL27) to the epidermis. (b) Factors controlling the deregulation of apoptosis in C-PTL-
NOS. Interplay between downregulation of FAS and CASP10 and upregulation of T-cell signaling genes. 
c-FLIP, FLICE-inhibitory protein; IKK, inhibitor of κβ kinase; NIK, NF-κB-inducing kinase; P, phosphorylated; 
Pro-CASP8/10, pro-caspase 8/10; TCR, T-cell receptor; TRAF, tumor necrosis factor receptor–associated factor.
aggressive behavior due  
to deregulation of apoptosis
Gene expression analysis in C-PTL-
NOS differed significantly from that 
of C-ALCL, including increased 
expression of T-cell signaling genes 
(PRKCQ and FYN) and diminished 
expression of apoptosis-related genes 
(FAS and CASP10). van Kester and 
colleagues suggest that C-PTL-NOS 
patients’ less favorable prognosis and 
resistance to treatment may be due to 
the oncogenic activity of PRKCQ and 
loss of expression of the FAS receptor, 
respectively.
Loss of FAS (CD95) is associated with 
the development of a specific lympho-
proliferative condition, the autoimmune 
lymphoproliferative syndrome (Sneller 
et al., 1997), with an increased risk of 
developing lymphoma. Recent stud-
ies demonstrate that FAS is expressed 
preferentially in cutaneous CD30+ 
lymphomas and suggest that FAS 
plays a role in the spontaneous regres-
sion of CD30+ skin lesions (Levi et al., 
2000). Therefore, loss of FAS could be 
closely associated with the aggres-
sive course observed in C-PTL-NOS. 
However, resistance to apoptosis can 
also occur as a consequence of the 
aberrant expression of intracellular 
apoptosis inhibitors in tumor cells. 
Among them is the FLICE-inhibitory 
protein (c-FLIP), an intracellular pro-
tein that is highly homologous to 
caspases 8 and 10 and that is able to 
block the autoproteolytic cleavage of 
caspase 8 that is normally induced 
upon triggering FAS-mediated apop-
tosis (Wu et al., 2009). Furthermore, 
an interplay between alterations in 
T-cell signaling and FAS could play an 
important role in the pathogenesis of 
C-PTL-NOS (Figure 1b).
The findings of van Kester and 
colleagues (2010), when consid-
ered along with observations made 
by others, support the notion that 
chemokine-regulated skin homing, 
NF-κB activation through CD30, and 
defective regulation of T-cell apopto-
sis followed by alterations in FAS and 
T-cell signaling are responsible for 
the different behaviors and outcomes 
of C-ALCL and C-PTL-NOS. These 
characteristics may depend partially 
on the numerous chromosomal 
imbalances identified by the authors. 
Although we still do not know all the 
factors that account for such different 
outcomes, the report can be seen as 
a major step toward elucidating the 
pathogenesis and identification of 
potential biomarkers for these types 
of CTLC.
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